Jane Nelson
Operational research support manager
Qualifications:
Bachelor of Nursing, Deakin University, 1993; Certificate IV in Training and Assessment, Australian College of Training and Employment, 2011.
Location:
Darwin - Royal Darwin Hospital campus
Biography:
Jane has a Bachelor of Nursing from Deakin University and completed her graduate nurse program at ‘The Royal Children’s Hospital’ Melbourne.
Jane has over a decade of experience in good clinical practice working in vaccine trials as a research nurse and later project manager in both Australia and overseas.
Jane has over a decade of experience in good clinical practice working in vaccine trials as a research nurse and later project manager in both Australia and overseas.
In her present position Jane has consolidated the operational management of four active clinical research programs with over 15 staff working across the Northern Territory in a range of contexts. Jane ensures all aspects of good clinical practice are maintained in the conduct of this research.
Research Themes
- PneuMum: a randomised controlled trial of pneumococcal polysaccharide vaccination for Aboriginal and Torres Strait Islander mothers to protect their babies from ear disease
- Skin sore trial: An open label randomised controlled trial to determine if 5 days of once-daily oral trimethoprim-sulfamethoxazole or three days of twice-daily oral trimethoprim-sulfamethoxazole will lead to non-inferior cure rates of impetigo compared to a single dose of intramuscular benzathine penicillin G (the current standard treatment) in children living in remote Aboriginal communities between the age of 12 weeks to less than 13 years
- Ivermectin MDA: beating scabies and strongyloidiasis in a remote Aboriginal community in the Northern Territory
- PREV-IX_COMBO: a randomised controlled trial of pneumococcal conjugate vaccines Synflorix and Prevenar13 in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): immunogenicity, carriage and otitis media outcomes
- The Pneumococcal immunisation protection and awareness project (PIPPA): a non-randomised phase IV study of the immune response to 23-valent pneumococcal polysaccharide vaccine amongst persons aged 15 to 64 years in the Northern Territory of Australia who are Indigenous persons due for a first or second dose of 23vPPV or previously unimmunised non-Indigenous persons.